Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
Galectin Therapeutics Inc. (GALT)
Last galectin therapeutics inc. earnings: 11/12 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.galectintherapeutics.com/investor-relations
Company Research
Source: GlobeNewswire
NORCROSS, Ga., April 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today the presentation of a late-breaker oral presentation on Saturday April 14, 2018 at 16:00 CET in the Main Plenary at The International Liver CongressTM 2018, European Association for the Study of the Liver (EASL) in Paris, France. Naga P. Chalasani, M.D., Associate Dean for Clinical Research; Director, Division of Gastroenterology and Hepatology at Indiana University School of Medicine; and co-lead principal investigators on Galectin Therapeutics’ recent Phase 2b NASH-CX trial, will give an oral presentation during a late breaker session, entitled “A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension.” The session will focus on the Company’s recent Phase 2b NASH-CX trial results and the innovative work it is
Show less
Read more
Impact Snapshot
Event Time:
GALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GALT alerts
High impacting Galectin Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GALT
News
- Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point [Seeking Alpha]Seeking Alpha
- Galectin Therapeutics Inc. (NASDAQ: GALT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development [Yahoo! Finance]Yahoo! Finance
- Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical DevelopmentGlobeNewswire
- Non-Alcoholic Steatohepatitis Treatment Market revenue to reach USD 48.3 Billion by 2035, says Research Nester [Yahoo! Finance]Yahoo! Finance
GALT
Earnings
- 11/13/23 - Miss
GALT
Sec Filings
- 3/4/24 - Form 4
- 2/16/24 - Form 3
- 2/7/24 - Form 4
- GALT's page on the SEC website